Barcelona Institute for Global Health
- Country
- 🇪🇸Spain
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.isglobal.org/ca/
Clinical Trials
25
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Preparing for Maternal GBS Vaccine Trials in Africa
- Conditions
- Group B StreptococcusInvasive Bacterial Diseases (IBD)Maternal Immunization
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Barcelona Institute for Global Health
- Target Recruit Count
- 18100
- Registration Number
- NCT06833957
- Locations
- 🇰🇪
Mariakani Sub-County Hospital, Mariakani, Coast, Kenya
🇰🇪Rabai Sub County Hospital, Rabai, Kilifi, Kenya
🇲🇼Queen Elizabeth Central Hospital, Blantyre, Blantyre District, Malawi
Nature Based Therapy With Mindful Walks in Urban Coastal Settings for Metabolic Syndrome - Barcelona (Spain)
- Conditions
- Metabolic Syndrome XStress
- First Posted Date
- 2024-10-02
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Barcelona Institute for Global Health
- Target Recruit Count
- 140
- Registration Number
- NCT06622629
- Locations
- 🇪🇸
ISGlobal, Barcelona, Spain
L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)
- Conditions
- Child, OnlyInfectious DiseaseInfections
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Barcelona Institute for Global Health
- Target Recruit Count
- 2200
- Registration Number
- NCT06426147
A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)
- Conditions
- Child, OnlyFebrile IllnessInfectious Disease
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Barcelona Institute for Global Health
- Target Recruit Count
- 5212
- Registration Number
- NCT06422338
- Locations
- 🇲🇿
Mopeia Sede Health Centre, Mopeia, Mozambique
COPD Exacerbation Modelling Using Unobtrusive Sensors - the TOLIFE Clinical Study A
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Barcelona Institute for Global Health
- Target Recruit Count
- 150
- Registration Number
- NCT06172712
- Locations
- 🇩🇪
Pulmonary Research Institute, Großhansdorf, Schleswig-Holstein, Germany
🇮🇹Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
🇪🇸Hospital del Mar Research Institute, Barcelona, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Ivermectin Mass Treatment Reduces Malaria Transmission by 26% in Landmark BOHEMIA Trial
The BOHEMIA trial, the largest study on ivermectin for malaria to date, demonstrated a 26% reduction in new malaria infections when administered alongside standard bed nets in Kenya.